Actuate Therap 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
elraglusib (9-ING-41) / Actuate Therap
NCT05077800: FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer

Recruiting
2
70
US
FOLFIRNINOX, Losartan, Cozaar, 9-ING-41
Colin D. Weekes, M.D., PhD, Actuate Therapeutics Inc., Lustgarten Foundation
Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic
12/25
07/26
NCT05010629: 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Active, not recruiting
2
35
US
9-ING-41, Carboplatin, Paraplatin
Glenn J. Hanna, Actuate Therapeutics Inc.
Salivary Gland Cancer, Recurrent Salivary Gland Cancer, Metastatic Cancer, Adenoid Cystic Carcinoma
02/25
04/27
NCT04218071: Actuate 1901: 9-ING-41 in Myelofibrosis

Completed
2
17
US
Ruxolitinib, Jakafi, 9-ING-41, 9-ING-41 Compound
Actuate Therapeutics Inc.
Myelofibrosis
10/22
01/24
Actuate 1801, NCT03678883 / 2018-003739-32: 9-ING-41 in Patients with Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc., Actuate Therapeutics Inc
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
01/25
01/26
RiLEY, NCT05239182: 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

Active, not recruiting
2
32
US
9-ING-41, Retifanlimab, INCMGA00012, Gemcitabine, Abraxane
Anwaar Saeed, Actuate Therapeutics Inc., Incyte Corporation
Pancreatic Adenocarcinoma
12/24
06/25
2018-003739-32: A clinical trial of a new drug known as 9-ING-41, that will take place in patients with tumors or cancers that affect the blood and lymph system. 9-ING-41 will be assessed as a standalone drug as well as being assessed when taken with chemotherapy drugs

Not yet recruiting
1/2
350
Europe
9-ING-41, Solution for infusion
Actuate Therapeutics Inc, Actuate Therapeutics Inc
Refractory Hematologic Malignancies or Solid Tumors, Advanced Cancers, Diseases [C] - Cancer [C04]
 
 
NCT04239092: 9-ING-41 in Pediatric Patients with Refractory Malignancies.

Recruiting
1
68
US
9-ING-41, 9-ING-41 COMPOUND, Irinotecan, CPT-11, Temozolomide, Temodar, Cyclophosphamide, Cyclophosphamide IV, Topotecan, Topotecan IV
Actuate Therapeutics Inc.
Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor, Pediatric Cancer, Pediatric Brain Tumor, Neuroblastoma, Neuroblastoma Recurrent, Pediatric Lymphoma, Pediatric Meningioma, Diffuse Intrinsic Pontine Glioma
12/24
12/24
RiLEY, NCT06896188: 9-ING-41 Combined with Retifanlimab, Plus Modified FOLFIRINOX for Patients with Advanced Pancreatic Adenocarcinoma

Not yet recruiting
1
12
US
Retifanlimab, ZYNYZ, Chemotherapy, 9-ING-41, Elraglusib
Anwaar Saeed, Actuate Therapeutics Inc., Incyte Corporation
Pancreatic Adenocarcinoma
05/27
12/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
elraglusib (9-ING-41) / Actuate Therap
NCT05077800: FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer

Recruiting
2
70
US
FOLFIRNINOX, Losartan, Cozaar, 9-ING-41
Colin D. Weekes, M.D., PhD, Actuate Therapeutics Inc., Lustgarten Foundation
Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic
12/25
07/26
NCT05010629: 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Active, not recruiting
2
35
US
9-ING-41, Carboplatin, Paraplatin
Glenn J. Hanna, Actuate Therapeutics Inc.
Salivary Gland Cancer, Recurrent Salivary Gland Cancer, Metastatic Cancer, Adenoid Cystic Carcinoma
02/25
04/27
NCT04218071: Actuate 1901: 9-ING-41 in Myelofibrosis

Completed
2
17
US
Ruxolitinib, Jakafi, 9-ING-41, 9-ING-41 Compound
Actuate Therapeutics Inc.
Myelofibrosis
10/22
01/24
Actuate 1801, NCT03678883 / 2018-003739-32: 9-ING-41 in Patients with Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc., Actuate Therapeutics Inc
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
01/25
01/26
RiLEY, NCT05239182: 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

Active, not recruiting
2
32
US
9-ING-41, Retifanlimab, INCMGA00012, Gemcitabine, Abraxane
Anwaar Saeed, Actuate Therapeutics Inc., Incyte Corporation
Pancreatic Adenocarcinoma
12/24
06/25
2018-003739-32: A clinical trial of a new drug known as 9-ING-41, that will take place in patients with tumors or cancers that affect the blood and lymph system. 9-ING-41 will be assessed as a standalone drug as well as being assessed when taken with chemotherapy drugs

Not yet recruiting
1/2
350
Europe
9-ING-41, Solution for infusion
Actuate Therapeutics Inc, Actuate Therapeutics Inc
Refractory Hematologic Malignancies or Solid Tumors, Advanced Cancers, Diseases [C] - Cancer [C04]
 
 
NCT04239092: 9-ING-41 in Pediatric Patients with Refractory Malignancies.

Recruiting
1
68
US
9-ING-41, 9-ING-41 COMPOUND, Irinotecan, CPT-11, Temozolomide, Temodar, Cyclophosphamide, Cyclophosphamide IV, Topotecan, Topotecan IV
Actuate Therapeutics Inc.
Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor, Pediatric Cancer, Pediatric Brain Tumor, Neuroblastoma, Neuroblastoma Recurrent, Pediatric Lymphoma, Pediatric Meningioma, Diffuse Intrinsic Pontine Glioma
12/24
12/24
RiLEY, NCT06896188: 9-ING-41 Combined with Retifanlimab, Plus Modified FOLFIRINOX for Patients with Advanced Pancreatic Adenocarcinoma

Not yet recruiting
1
12
US
Retifanlimab, ZYNYZ, Chemotherapy, 9-ING-41, Elraglusib
Anwaar Saeed, Actuate Therapeutics Inc., Incyte Corporation
Pancreatic Adenocarcinoma
05/27
12/28

Download Options